Log in to search using one of your social media accounts:

 

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light-chain amyloidosis
Conclusion We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 20, 2017 Category: Cancer & Oncology Source Type: research

Relevance of Bone Marrow Transplantation Nursing Training Program at King Faisal Specialist Hospital and Research Centre for National and Regional Nurses
Publication date: Available online 18 August 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Reguia Belkhedim (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 18, 2017 Category: Cancer & Oncology Source Type: research

Presence of FISH abnormalities is associated with plasma cell burden in light chain amyloidosis
Conclusion We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Impact of Vitamin D Deficiency on Increased Blood Eosinophil Counts
Conclusion Vitamin D deficiency was associated with higher blood eosinophil count. These results support the possible role of vitamin D in the eosinophil immune response. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Acute Promyelocytic Leukemia in a Patient with Chronic Lymphocytic Leukemia —A Case Report
Publication date: Available online 16 August 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Prajwal Boddu, Ellen Schlette, Beenu Thakral, Guillin Tang, Naveen Pemmaraju, Tapan Kadia, Alessandra Ferrajoli, Farhad Ravandi, William Wierda, Nitin Jain Chronic lymphocytic leukemia (CLL) is known to be associated rarely with myeloid malignancies such as acute myelogenous leukemia. In this article, we report an extremely rare occurrence of acute promyelocytic leukemia in a patient with CLL. A 71-year-old man first presented to our clinic with a diagnosis of CLL and worsening motor neuropathy symptoms. It was su...
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Ruxolitinib for Secondary Hemophagocytic Lymphohistiocytosis: First Case Report
We describe a case of secondary HLH that did not respond favorably to conventional treatments. Serum inflammatory markers continued to rise significantly with clinical deterioration and worsening pancytopenia. The severe thrombocytopenia and neutropenia were deemed to have contributed to a spontaneous subdural hematoma and candidemia, respectively. Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time. Following initiation, there was improvement seen in several disease markers, including serum ferritin, lactate dehydrogenase, fibrino...
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Multimodality Therapy Improves Survival in Intramedullary Spinal Cord Metastasis of Lung Primary
Conclusion Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - August 17, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Deva Sharma Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD); however, its use is limited by lack of suitable human leukocyte antigen (HLA)-matched donors and decreased application in older patients with significant morbidity. Myeloablative, HLA-identical sibling transplantation in children with SCD offers excellent long-term survival, with overall and event-free survival rates of 95% and 92%, respectively. However, the risk ...
Source: Hematology Oncology and Stem Cell Therapy - August 2, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation in Pakistan – country report
Publication date: Available online 22 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parvez Ahmed, Tahir Sultan Shamsi, Salman Naseem Adil, Tariq Mahmood Satti, Qamar un Nisa Chaudhry, Syed Kamran Mahmood, Kamran Rashid, Saqib Ansari, Natasha Ali, Tariq Ghafoor (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 27, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Pakistan - Country Report
Publication date: Available online 22 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parvez Ahmed, Tahir Sultan Shamsi, Salman Naseem Adil, Tariq Mahmood Satti, Qamar un Nisa Chaudhry, Syed Kamran Mahmood, Kamran Rashid, Saqib Ansari, Natasha Ali, Tariq Ghafoor (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 23, 2017 Category: Cancer & Oncology Source Type: research

Current Concepts on Hematopoietic Stem Cell Transplantation Outcome Registries; Emphases on Resource Requirements for New Registries
Publication date: Available online 19 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Fazal Hussain, Naeem Chaudhri, Feras Alfraih, Mahmoud Aljurf There is tremendous variability in size, scope, and resource requirements for registries depending on the number of patients and participating sites. The outcome registries are organized systems to collect uniform data using an observational study methodology. Patient registries are used to determine specified outcomes for a population for predetermined scientific, clinical, or policy purposes. Historically, outcome registries established in the developmen...
Source: Hematology Oncology and Stem Cell Therapy - July 20, 2017 Category: Cancer & Oncology Source Type: research

Cost and Quality Issues in Establishing Hematopoietic Cell Transplant Program in Developing Countries
Publication date: Available online 14 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shahrukh K. Hashmi, Alok Srivastava, Walid Rasheed, Salman Adil, Tong Wu, Madan Jagasia, Amr Nassar, William Y.K. Hwang, Amir Ali Hamidieh, Hildegard T. Greinix, Marcelo C. Pasquini, Jane F. Apperley, Mahmoud Aljurf The hematopoietic cell transplant (HCT) activity has grown significantly over the past two decades in both developing and developed countries. Many challenges arise in establishing new HCT programs in developing countries, due to scarcity of resources and manpower in expertise in HCT. While cost issues c...
Source: Hematology Oncology and Stem Cell Therapy - July 15, 2017 Category: Cancer & Oncology Source Type: research

Complications of hematopoietic stem cell transplantation: Bacterial infections
Publication date: Available online 3 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Bacterial infections remain a common complication of hematopoietic stem cell transplantation (HSCT), especially in the pre-engraftment phase. The risk of bacterial infections is mainly related to neutropenia, mucositis, and the presence of vascular lines. Most parts of the world have witnessed a shift in epidemiology toward Gram-negative bacteria; a large proportion of which are resistant to fluoroquinolones, extended-spectrum beta-lactams, carbapenems, and in some units even colisti...
Source: Hematology Oncology and Stem Cell Therapy - July 12, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic stem cell transplantation for acute myeloid leukemia: A review
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Bipib N. Savani Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and improvements in survival. Recent era has witnessed an explosive information about the molecular pathophysiology of AML. By early identification of pa...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Algeria
Publication date: Available online 11 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): M.A. Bekadja, M. Brahimi, S. Osmani, N. Yafour, A. Krim, F. Serradj, S. Talhi, K. Amani, R. Bouhass Algeria is a country of 40.4 million inhabitants half of whom are younger than 30 years. In Algeria, healthcare insurance covers 90% of the population. Healthcare is free and it is supported by the Ministry of Health. Sixteen university hospitals exist in Algeria and only two (Algiers and Oran) practice bone marrow transplant. Hematologic malignancies in adults account for 10% (∼4,000 new cases/y) of the malignanc...
Source: Hematology Oncology and Stem Cell Therapy - July 11, 2017 Category: Cancer & Oncology Source Type: research

Plasmablastic Lymphoma Presenting as Exophytic Skin Lesions
Publication date: Available online 5 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Riad El Fakih, Muhamad Almahayni, Maamoun Alsermani (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 7, 2017 Category: Cancer & Oncology Source Type: research

Complications of Hematopoietic Stem Transplantation: Bacterial infections
Publication date: Available online 3 July 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Bacterial infections remain a common complication of hematopoietic stem cell transplantation (HSCT), especially in the pre-engraftment phase. The risk of bacterial infections is mainly related to neutropenia, mucositis, and the presence of vascular lines. Most parts of the world have witnessed a shift in epidemiology towards Gram-negative bacteria; a large proportion of which are resistant to fluoroquinolones, extended-spectrum beta-lactams, carbapenems, and in some units even colist...
Source: Hematology Oncology and Stem Cell Therapy - July 4, 2017 Category: Cancer & Oncology Source Type: research

Establishing an Autologous versus Allogeneic Hematopoietic Cell Transplant Program in Nations with Emerging Economies
The objective of the transplant procedure is to improve the survival and quality of life of patients. The regional difference that one notices in emerging countries about the higher number of allo-HCT compared with auto-HCT procedures performed is primarily based on suboptimal health-care network in treating various malignant disorders that are the primary indication for auto-stem cell transplantation. In this context, nonmalignant disorders such as bone marrow failure syndromes, inherited genetic disorders, and hemoglobinopathies have become the major indication for stem cell transplantation. Better understanding of these...
Source: Hematology Oncology and Stem Cell Therapy - July 4, 2017 Category: Cancer & Oncology Source Type: research

Practical Implementation – Essential Elements Resource Tool
In conclusion, new and developing stem cell transplantation programs should focus on quality and safety and step on the path towards full accreditation. The HSCT community must continue its efforts to offer education and training to support developing programs to attain accreditation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 30, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in Qatar: One-Year Anniversary
Publication date: Available online 29 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohammad Bakr, Ibrahim Al-Hijji, Naziha Menasria, Zeyd Merenkov, Safaa Al-Azzawi, Ruba Taha, Amaal Gulied, Catherine Anne Gillespie, Said Dermime, Effie Liakopoulou, Alexander Knuth Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for many hematologic and nonhematologic conditions. As a successful outcome of Qatar’s National Cancer Strategy, the HSCT program was started in the National Center for Cancer Care and Research (NCCCR) in October 2015. The HSCT program in NCCCR is th...
Source: Hematology Oncology and Stem Cell Therapy - June 30, 2017 Category: Cancer & Oncology Source Type: research

Current Indication for Hematopoietic Cell Transplantation in Adults
Publication date: Available online 30 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shinichiro Okamoto With advances in transplantation technology and supportive care practices, hematopoietic cell transplantation (HCT) has become relatively safer and the applicability of HCT continues to expand. However, appropriate selection of transplant candidates remains challenging. Identifying adult patients who may benefit from HCT involves consideration of patient and disease factors, including overall health, prior therapies, age, comorbidity, and disease/disease risk. The eligibility of transplants should...
Source: Hematology Oncology and Stem Cell Therapy - June 30, 2017 Category: Cancer & Oncology Source Type: research

Nursing Challenges Caring for Bone Marrow Transplantation Patients with Graft Versus Host Disease
Publication date: Available online 28 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Joyce Neumann (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 29, 2017 Category: Cancer & Oncology Source Type: research

Kuwait Bone Marrow Transplantation Activities
Publication date: Available online 22 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Salem H Alshemmar, Reem Ameen Kuwait is located in the Arabian Gulf and has a population of 3.5 million. The stem cell transplantation program started in 2000. Autologous peripheral blood stem cell transplantation started first, as it was easier technically to establish. In 2011, the allogeneic program started with focus on acute leukemia and hemoglobinopathies. The success of both programs required teamwork and support of health planners. We are in the process of establishing a bone marrow donor registry. The issue...
Source: Hematology Oncology and Stem Cell Therapy - June 23, 2017 Category: Cancer & Oncology Source Type: research

Thalassemia Major: Transfusion and Chelation or Transplantation
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Said Yousuf Mohamed Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year. Without transfusion or transplantation, patients with thalassemia major are expected to die within months of diagnosis. However, long-term transfusion and chelation therapy is highly challenging for many developing countries where the disease is prevalent, representing a major and unsustainable health burden. Stem cell transplantation is the only cure for tha...
Source: Hematology Oncology and Stem Cell Therapy - June 21, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation in Hematological Malignancies: Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Publication date: Available online 20 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola Kassim, Bipin N. Savani Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and improvements in survival. Recent era has witnessed an explosive information about the molecular pathophysiology of AML. By early identification of patie...
Source: Hematology Oncology and Stem Cell Therapy - June 21, 2017 Category: Cancer & Oncology Source Type: research

End of therapy minimal residual disease (MRD) measurement in children with ALL does not predict relapse
Publication date: Available online 17 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Tahani Hani Sarrawi, Ismael Zayyat, Fareed Barakat, Maha Rezeq, Salam Abu Jmaian, Faris Madanat (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 20, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation in the Sultanate of Oman
Publication date: Available online 17 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Murtadha Al-Khabori, Mohammed Al-Huneini The Sultanate of Oman is one of the Arabian Gulf countries with a total population of 4,414,051 as of mid 2016, of whom 2,427,825 are Omanis. The gross national income per capita was 7327.7 RO (Omani rial; equivalent to US$19,033) in 2014. There are two hematopoietic stem cell transplantation (HSCT) centers in Oman: the Sultan Qaboos University Hospital (SQUH; allogeneic and autologous) and the Royal Hospital (RH; autologous). HSCT activity in Oman started in 1995 at the SQUH...
Source: Hematology Oncology and Stem Cell Therapy - June 20, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adult Patients
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Riad El Fakih, Syed Ahmed, Feras Alfraih, Amr Hanbali Acute lymphoblastic leukemia (ALL) consists of precursor B ALL or T ALL phenotypes. In the pediatric population, ALL patients enjoy an 80% long-term survival with the current pediatric chemotherapy protocols as compared with 50% long-term survival in the adult population. In adults, complete remission rates are similar to those of pediatric patients; however, long-term survival is much lower with the majority of deaths attributable to relapsed disease. Postremiss...
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Comparison of Cyclophosphamide –Thalidomide–Dexamethasone to Bortezomib–Cyclophosphamide–Dexamethasone as Induction Therapy for Multiple Myeloma Patients in Brazil
Conclusion VCD afforded better responses than the CTD protocol, and improved patient condition before autologous HSCT. However, more studies are necessary including more patients and addressing various clinical conditions, besides the analysis of cost-effectiveness of these treatments. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Giant-Cell Tumor of Bone with Pathological Evidence of Blood Vessel Invasion
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Shadi Khalil, Rachana Yendala, Nicholas D'Cunha, Fred Hardwicke, Mohamed Shanshal (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Hematological Parameters and Red Blood Cell Morphological Abnormality of Glucose-6-Phosphate Dehydrogenase Deficiency Co-Inherited With Thalassemia
Conclusion G-6-PD deficiency co-inherited with thalassemia in males was present in 10% of the participants, resulting in worsening of red blood cell pathology compared with inheritance of thalassemia alone. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia: The Changing Landscape
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Adetola A. Kassim, Deva Sharma Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD); however, its use is limited by lack of suitable human leukocyte antigen (HLA)-matched donors and decreased application in older patients with significant morbidity. Myeloablative, HLA-identical sibling transplantation in children with SCD offers excellent long-term survival, with overall and event-free survival rates of 95% and 92%, respectively. However, the risk ...
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Study of Platelet Activation, Hypercoagulable State, and the Association with Pulmonary Hypertension in Children with β-Thalassemia
Conclusion A chronic hypercoagulable state and platelet activation is present in children with β-thalassemia. Splenectomy and transfusion infrequency are the main risk factors noted to be associated with such hypercoagulable state and platelet activation and consequently the PH among our thalassemic patients. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Treatment with Methotrexate, Rituximab, and Cytosine Arabinoside Followed by Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: A Single-center Experience
Conclusion R–MTX–ARA-C followed by autologous stem cell transplantation seems a promising strategy with high response rates in PCNSL. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation in Fanconi Anemia and Dyskeratosis Congenita: A Minireview
Publication date: Available online 15 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mouhab Ayas Bone marrow failure syndrome is an epithet of bone marrow failure (all or single-cell lineage) that is attributable to an underlying genetic aberration usually with a constellation of somatic abnormalities. Multiple inheritance patterns have been described in these disorders; many are transmitted in an autosomal recessive pattern, which may consequently lead to a higher prevalence of such illnesses in homogeneous societies such as Saudi Arabia, where consanguineous marriages are not uncommon. At King Fai...
Source: Hematology Oncology and Stem Cell Therapy - June 16, 2017 Category: Cancer & Oncology Source Type: research

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: Emerging Questions, Newer Agents, and Changing Paradigm
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Saad Akhtar Primary treatment for adult and pediatric patients with Hodgkin lymphoma (HL) using current multiagent anthracycline-based chemotherapy with or without radiation therapy will cure approximately > 70% of the patients; > 95% for early stage with a favorable risk profile and 70–75% with advanced stage and high risk features. Managing refractory and relapsed disease, however, remains a challenge. High dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) can salvage ...
Source: Hematology Oncology and Stem Cell Therapy - June 15, 2017 Category: Cancer & Oncology Source Type: research

Emerging Concepts in Cytomegalovirus Infection Following Hematopoietic Stem Cell Transplantation
Publication date: Available online 14 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Jose F. Camargo, Krishna V. Komanduri Despite the refinements in molecular methods for the detection of cytomegalovirus (CMV) and the advent of highly effective preemptive strategies, CMV remains a leading cause of morbidity and mortality in hematopoietic cell transplant (HCT) recipients. CMV can cause tissue-invasive disease including pneumonia, hepatitis, colitis, retinitis, and encephalitis. Mortality in HCT recipients with CMV disease can be as high as 60%. CMV infection has been associated with increased risk o...
Source: Hematology Oncology and Stem Cell Therapy - June 15, 2017 Category: Cancer & Oncology Source Type: research

Reduced-Intensity versus Myeloablative Allogeneic Transplantation
Publication date: Available online 14 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Daniel J. Weisdorf Allotransplantation cures patients by cytoreduction and the graft-versus-tumor (leukemia; graft-versus-leukemia [GVL]) alloresponse; both eliminate residual disease. The spectrum of conditioning intensity influences toxicities and non-relapse mortality. The spectrum of tumor sensitivity to the GVL response influences relapse. Balancing tolerable toxicities (influenced by patients’ performance status and comorbidities) is also influenced by the graft. Intense immunosuppression (for engraftmen...
Source: Hematology Oncology and Stem Cell Therapy - June 15, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation: Training Challenges and Potential Opportunities through Networking and Integration of Modern Technologies to the Practice Setting
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mohamed A. Kharfan-Dabaja, Mahmoud Aljurf Hematopoietic cell transplantation (HCT), particularly allogeneic HCT, is a complex and a high-risk procedure requiring expertise to manage potential treatment complications. Published data supports the value of quality management systems in improving post-transplant outcomes; however, there are no universally established, or agreed upon, criteria to assess adequacy of training of physicians, transplant or nontransplant, and supporting staff, among others. It is of paramount...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Recent Advances in Understanding Multiple Myeloma
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Parameswaran Hari There have been major recent advancements in the understanding and management of multiple myeloma which in turn has led to unprecedented survival outcomes for patients. Diagnostic and response criteria have been recently revised. Our understanding of clonal progression, evolution, and clonal tides will inform therapeutic choices and appropriate treatment for patients. Response rates to initial induction with modern triplet therapies containing proteasome inhibitors and immunomodulators have made th...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Trends in Hematopoietic Stem Cell Transplant Activity in Lebanon
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali Bazarbachi, Ammar Zahreddine, Radwan Massoud, Jean Cheikh, Colette Hanna, Fadi Nasr, Miguel Abboud, Ahmad Ibrahim Hematopoietic stem cell transplantation (HSCT) has been accessible to the population residing in Lebanon and surrounding countries since 1997. HSCT programs were developed in two major hospitals in Beirut: American University of Beirut Medical Center (AUBMC) and Makassed General Hospital. Mount Lebanon Hospital initiated an autologous HSCT activity later. Between 2012 and 2016, the HSCT activity in L...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Long-term Complications after Hematopoietic Cell Transplantation
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Navneet S. Majhail The prevalence of autologous and allogeneic hematopoietic cell transplantation (HCT) survivors continues to increase. Among patients whose disease remains in remission for the first 2–5 years after transplantation, it is estimated that approximately 80–90% will be alive over the subsequent 10 years. However, the relative mortality rates of such patients continue to remain higher than those of their general population peers, with late complications contributing to significant long-term ...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Hematopoietic Cell Transplantation for Diffuse Large B-Cell and Follicular Lymphoma: Current Controversies and Advances
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Narendranath Epperla, Mehdi Hamadani Non-Hodgkin’s lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with diverse biologic, histologic, and clinical features. With a better understanding of the molecular pathogenesis, recently there have been major advances in the treatment of NHLs including addition of novel monoclonal antibodies, targeted therapies, and immune activators to the therapy armamentarium. Despite these remarkable developments, autologous hematopoietic cell transplantation (...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Complications of Hematopoietic Stem Transplantation: Fungal Infections
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Ali S. Omrani, Reem S. Almaghrabi Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are at increased risk of invasive fungal infections, especially during the early neutropenic phase and severe graft-versus-host disease. Mold-active prophylaxis should be limited to the highest risk groups. Empiric antifungal therapy for HSCT with persistent febrile neutropenia is associated with unacceptable response rates, unnecessary antifungal therapy, increased risk of toxicity, and inflated costs. Em...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Memory T Cells: A Helpful Guard for Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-versus-Host Disease
Publication date: Available online 13 June 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Wei Huang, Nelson J. Chao Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (AHSCT) and the major cause of nonrelapse morbidity and mortality of AHSCT. In AHSCT, donor T cells facilitate hematopoietic stem cell (HSC) engraftment, contribute to anti-infection immunity, and mediate graft-versus-leukemia (GVL) responses. However, activated alloreactive T cells also attack recipient cells in vital organs, leading to GVHD. Different T-cell subsets, including na...
Source: Hematology Oncology and Stem Cell Therapy - June 14, 2017 Category: Cancer & Oncology Source Type: research

Myasthenia Gravis after Allogeneic Bone Marrow Transplantation: A Case Report and Literature Review
Publication date: Available online 18 May 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Yutaka Tsutsumi, Takashi Kamiishi, Ryo Kikuchi, Shinichi Ito, Satomi Matsuoka, Takanori Teshima A 52-year-old man with acute myeloid leukemia underwent allogeneic hematopoietic stem cell transplantation and developed extensive chronic graft-versus-host disease and myasthenia gravis (MG), which became involved with oculobulbar and proximal upper and lower limb weakness in 677 days. In the literature, we identified 24 cases where MG developed after allo-SCT. Graft-versus-host disease development and male recipients of ...
Source: Hematology Oncology and Stem Cell Therapy - May 19, 2017 Category: Cancer & Oncology Source Type: research

Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Publication date: Available online 19 May 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Hind Rafei, Mohamed A. Kharfan-Dabaja More effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53. Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, has demonstrated impressive response rates in the relapsed/refractory setting, including in the setting of Del17p and/or TP53 mutations. Venetoclax, an inhibitor of BC...
Source: Hematology Oncology and Stem Cell Therapy - May 19, 2017 Category: Cancer & Oncology Source Type: research

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation.
Conclusion Low fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 26, 2017 Category: Cancer & Oncology Source Type: research

Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients
Publication date: Available online 6 April 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Bushra Salman, Mohammed Al-Za'abi, Mohammed Al-Huneini, David Dennison, Abdulhakeem Al-Rawas, Salam Al-Kindi, Khalil Al-Farsi, Melanie Tauro, Murtadha Al-Khabori Busulfan (Bu)-based preparative regimens in hematopoietic stem cell transplantation are commonly used. Previous studies have shown that Bu at a fixed dose of 3.2mg/kg/day (FBD) given intravenously decreases variability in drug pharmacokinetics and this decreases the dependency on therapeutic drug monitoring (TDM) of Bu. We compared the Bu dose given using T...
Source: Hematology Oncology and Stem Cell Therapy - April 25, 2017 Category: Cancer & Oncology Source Type: research

Mantle cell lymphoma: Contemporary diagnostic and treatment perspectives in the age of personalized medicine
Publication date: Available online 6 April 2017 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Jose Sandoval-Sus, Eduardo M. Sotomayor, Bijal D. Shah Mantle cell lymphoma is a clinically heterogeneous disease occurring within a heterogeneous patient population, highlighting a need for personalized therapy to ensure optimal outcomes. It is therefore critical to understand the benefits and risks associated with both intensive and deintensified approaches. In the following review we provide a therapeutic roadmap to strategically guide treatment for newly diagnosed and relapsed/refractory patients highlighting pi...
Source: Hematology Oncology and Stem Cell Therapy - April 11, 2017 Category: Cancer & Oncology Source Type: research